{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:16Z","timestamp":1792619056236,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102148","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T09:11:09Z","timestamp":1719911469000},"page":"102148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1128","authenticated-orcid":false,"given":"Akinori","family":"Minato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Furubayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-5937","authenticated-orcid":false,"given":"Hiroyuki","family":"Masaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoohyun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Kiyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kuroiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihito","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikko","family":"Tomisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102148_bib0001","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102148_bib0002","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102148_bib0003","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102148_bib0004","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102148_bib0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.urolonc.2023.06.006","article-title":"Antibody-drug conjugates for urothelial carcinoma","volume":"41","author":"Thomas","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102148_bib0006","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102148_bib0007","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2024.102148_bib0008","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102148_bib0009","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2147\/OTT.S299724","article-title":"Organ-specific tumor response to pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy","volume":"14","author":"Furubayashi","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clgc.2024.102148_bib0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102148_bib0011","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. version 1.1. 2009;45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.clgc.2024.102148_bib0012","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2024.102148_bib0013","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102148_bib0014","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10585-023-10217-7","article-title":"Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis","volume":"40","author":"Tian","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clgc.2024.102148_bib0015","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00345-021-03721-6","article-title":"The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis","volume":"39","author":"Shou","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2024.102148_bib0016","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I study of Single-Agent enfortumab vedotin in patients with Nectin-4-Positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102148_bib0017","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2024.102148_bib0018","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102148_bib0019","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102148_bib0020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jjco\/hyt096","article-title":"Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy","volume":"43","author":"Taguchi","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102148_bib0021","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","article-title":"Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan","volume":"191","author":"Abe","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102148_bib0022","doi-asserted-by":"crossref","first-page":"9.e11","DOI":"10.1016\/j.urolonc.2017.09.009","article-title":"Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes","volume":"36","author":"Faltas","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102148_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open."},{"key":"10.1016\/j.clgc.2024.102148_bib0024","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102148_bib0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/iju.14793","article-title":"Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden","volume":"29","author":"Nagumo","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102148_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221094879","article-title":"The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy","volume":"14","author":"Alqaisi","year":"2022","journal-title":"Ther Adv Med Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:57:09Z","timestamp":1738565829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001198"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102148","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102148"}}